|
AU2008201159A1
|
|
Polyclonal populations of bispecific molecules and methods of production and uses thereof
|
|
WO2008140487A2
|
|
Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use
|
|
WO2008042261A2
|
|
Anti-anthrax antibody, formulations thereof, and methods of use
|
|
WO2007097934A2
|
|
Methods and compositions for using erythrocytes as carriers for delivery of drugs
|
|
AU2007200022A1
|
|
Bispecific molecules and uses thereof
|
|
EP1814918A1
|
|
Use of cr1-binding molecules in clearance and induction of immune responses
|
|
CA2520389A1
|
|
Method and compositions for conversion of antibody activity
|
|
AU2004254166A1
|
|
Immunogenicity-reduced anti-CR1 antibody and compositions and methods of treatment based thereon
|
|
US2006153839A1
|
|
Production of bispecific molecules using polyethylene glycol linkers
|
|
AU2003295330A1
|
|
Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
|
|
AU2003241470A1
|
|
Purified composition of bispecific molecules and methods of production
|
|
EP1487487A2
|
|
Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
|
|
EP1379277A2
|
|
Polyclonal populations of bispecific molecules and methods of production and uses thereof
|
|
AU4155602A
|
|
Method of producing biospecific molecules by protein trans-splicing
|
|
AU5720601A
|
|
Bispecific molecules and uses thereof
|
|
AU2593901A
|
|
Therapeutic use of particles displaying pathogen-specific binding moieties
|
